• 1
    Chiorazzi N,Rai KR,Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 80415.
  • 2
    Damle RN,Wasil T,Fais F,Ghiotto F,Valetto A,Allen SL,Buchbinder A,Budman D,Dittmar K,Kolitz J,Lichtman SM,Schulman P, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 18407.
  • 3
    Hamblin TJ,Davis Z,Gardiner A,Oscier DG,Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 184854.
  • 4
    Klein U,Tu Y,Stolovitzky GA,Mattioli M,Cattoretti G,Husson H,Freedman A,Inghirami G,Cro L,Baldini L,Neri A,Califano A, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 162538.
  • 5
    Rosenwald A,Alizadeh AA,Widhopf G,Simon R,Davis RE,Yu X,Yang L,Pickeral OK,Rassenti LZ,Powell J,Botstein D,Byrd JC, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 163947.
  • 6
    Glass DJ,Bowen DC,Stitt TN,Radziejewski C,Bruno J,Ryan TE,Gies DR,Shah S,Mattsson K,Burden SJ,DiStefano PS,Valenzuela DM, et al. Agrin acts via a MuSK receptor complex. Cell 1996; 85: 51323.
  • 7
    Masiakowski P,Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 1992; 267: 2618190.
  • 8
    Valenzuela DM,Stitt TN,DiStefano PS,Rojas E,Mattsson K,Compton DL,Nunez L,Park JS,Stark JL,Gies DR,Thomas S,Le Beau M, et al. Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron 1995; 15: 57384.
  • 9
    Yoda A,Oishi I,Minami Y. Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans. J Recept Signal Transduct Res 2003; 23: 115.
  • 10
    Reddy UR,Phatak S,Pleasure D. Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains. Oncogene 1996; 13: 15559.
  • 11
    Harris NL,Jaffe ES,Diebold J,Flandrin G,Muller-Hermelink HK,Vardiman J,Lister TA,Bloomfield CD. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the clinical advisory committee meeting. Airlie House Virginia. November 1997. Histopathology 2000; 36: 6986.
  • 12
    Rezvany MR,Jeddi-Tehrani M,Rabbani H,Lewin N,Avila-Carino J,Osterborg A,Wigzell H,Mellstedt H. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. Br J Haematol 2000; 111: 60817.
  • 13
    Mikaelsson E,Daneshmanesh AH,Lüppert A,Jeddi-Tehrani M,Rezvany MR,Sharifian RA,Safaie R,Roohi A,Österborg A,Mellstedt H,Shokri F,Rabbani H. Fibromodulin-an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma. Blood 2005; 105: 482835.
  • 14
    Kokhaei P,Palma M,Hansson L,Osterborg A,Mellstedt H,Choudhury A. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol 2007; 35: 297304.
  • 15
    Willems P,Verhagen O,Segeren C,Veenhuizen P,Guikema J,Wiemer E,Groothuis L,Jong TB,Kok H,Bloem A,Bos N,Vellenga E, et al. Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch hematology-oncology group. Blood 2000; 96: 6370.
  • 16
    Rezvany MR,Jeddi-Tehrani M,Biberfeld P,Soderlund J,Mellstedt H,Osterborg A,Rabbani H. Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern. Br J Haematol 2001; 115: 26371.
  • 17
    Caligaris-Cappio F,Gobbi M,Bofill M,Janossy G. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med 1982; 155: 6238.
  • 18
    Cutrona G,Colombo M,Matis S,Reverberi D,Dono M,Tarantino V,Chiorazzi N,Ferrarini M. B lymphocytes in humans express ZAP-70 when activated in vivo. Eur J Immunol 2006; 36: 55869.
  • 19
    Baskar S,Kwong K,Hofer T,Levy J,Kennedy M,Lee E,Staudt L,Wilson W,Wiestner A,Rader C. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a potential therapeutic target antigen in human B cell chronic lymphocytic leukemia. Leuk Lymphoma 2007; 48 ( Suppl 1): S171.
  • 20
    Fukuda T,Endo T,Chen L,Lu D,Castro J,Widhope G,Rassenti L,Cantwell M,Prussak C,Carson D,Kipps TJ. CD154 gene therapy for chronic lymphocytic leukemia can elicit antibodies against ROR1, an oncofetal leukemia-associated surface antigen. Leuk Lymphoma 2007; 48 ( Suppl 1): S159.
  • 21
    Paganoni S,Anderson KL,Ferreira A. Differential subcellular localization of Ror tyrosine kinase receptors in cultured astrocytes. Glia 2004; 46: 45666.
  • 22
    Baskar S,Kwong K,Hofer T,Levy J,Kennedy M,Wilson W,Wiestner A,Rader C. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a potential target antigen for immunotherapy of human B cell chronic lymphocytic leukemia. J Immunother 2006; 29: 6712.
  • 23
    Yu L,Liu C,Vandeusen J,Becknell B,Dai Z,Wu YZ,Raval A,Liu TH,Ding W,Mao C,Liu S,Smith LT, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 2005; 37: 26574.
  • 24
    Fukuda T,Lu D,Carson DA,Kipps TJ. Restricted expression of the orphan tyrosine kinase receptor ror1 in chronic lymphocytic leukemia. Blood 2004; 104 ( Suppl 1): 221a.